Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENERAL ELECTRIC COGE · Entity 2813 | Director | April 02, 2018 | April 02, 2018 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 11, 2021 | June 08, 2021 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 11, 2022 | May 13, 2022 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director · Chief Executive Officer | August 17, 2009 | August 18, 2009 |
| Telesis Bio Inc.TBIO · Entity 15606 | 10% owner | June 05, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENERAL ELECTRIC CO
Report date April 02, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Fee Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,242 |
Reported balance
After 2018-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-02 · Grant · Acquired 5,512 · Balance 52,242 F1: Acquired at a price of $14.06 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director. F2: Each unit of phantom stock is the economic equivalent of one share of common stock. F3: Payable beginning one year after termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired at a price of $14.06 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director.
F2: Each unit of phantom stock is the economic equivalent of one share of common stock.
F3: Payable beginning one year after termination of service as a director.
Quanterix Corp
Report date January 11, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,270 |
Last balance in matching sequence
After 2021-06-07 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2021-06-04 · Exercise / conversion · Acquired 1,951 · Balance 11,031 F1: Includes 2,270 restricted stock units. Row 2 · 2021-06-04 · Exercise / conversion · Acquired 3,168 · Balance 14,199 F1: Includes 2,270 restricted stock units. Row 3 · 2021-06-04 · Sale · Disposed 7,610 · Balance 6,589 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F3: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.11. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. Row 4 · 2021-06-07 · Exercise / conversion · Acquired 4,732 · Balance 11,321 F1: Includes 2,270 restricted stock units. Row 5 · 2021-06-07 · Sale · Disposed 4,360 · Balance 6,961 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F4: This transaction was executed in multiple trades at prices ranging from $55.17 to $56.16. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. Row 6 · 2021-06-07 · Sale · Disposed 4,691 · Balance 2,270 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F5: This transaction was executed in multiple trades at prices ranging from $56.17 to $56.41. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2027-03-31 | Direct | 0 |
Reported balance
After 2021-06-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-04 · Exercise / conversion · Disposed 1,951 · Balance 0 F6: The option vests as to 25% of the shares on March 13, 2018 and vests as to an additional 2.083% of the shares per month thereafter until February 28, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.12 · Expires 2030-01-02 | Direct | 4,732 |
Reported balance
After 2021-06-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-06-04 · Exercise / conversion · Disposed 3,168 · Balance 4,732 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.12 · Expires 2030-01-02 | Direct | 0 |
Reported balance
After 2021-06-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-06-07 · Exercise / conversion · Disposed 4,732 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,270 restricted stock units.
F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F3: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.11. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $55.17 to $56.16. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $56.17 to $56.41. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The option vests as to 25% of the shares on March 13, 2018 and vests as to an additional 2.083% of the shares per month thereafter until February 28, 2021.
Quantum-Si Inc
Report date May 11, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2032-05-11 | Direct | 59,880 |
Reported balance
After 2022-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-11 · Grant · Acquired 59,880 · Balance 59,880 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Dekkers' continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Dekkers' continued service through the applicable vesting date.
THERMO FISHER SCIENTIFIC INC.
Report date August 17, 2009 · Filed August 18, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,554 |
Ending reported balance
After 2009-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2009-08-17 · Grant · Acquired 23,600 · Balance 47,481 F1: Represents shares awarded as performance restricted stock awards on November 9, 2006, for which the performance criteria have been satisfied. Row 2 · 2009-08-17 · Tax withholding · Disposed 4,927 · Balance 42,554 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 60,260 |
Reported balance
Holding disclosure · report date 2009-08-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 60,260 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares awarded as performance restricted stock awards on November 9, 2006, for which the performance criteria have been satisfied.
Telesis Bio Inc.
Report date June 05, 2023 · Filed June 08, 2023
Jointly reported with Novalis LifeSciences Investments II GP, LLC, Novalis LifeSciences Investments II, L.P., MEISTER PAUL M
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Redeemable Convertible Preferred Stock has a stated value of $100 (the "Stated Value") and accrues dividends daily at an initial rate of 8.0% per annum. The Stated Value, as adjusted to give effect to such dividends, is referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock is convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of the Issuer's Common Stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock is not convertible to the extent that such conversion would result in the holder of such Redeemable Convertible Preferred Stock, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2030-06-05 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2025-06-05 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Redeemable Convertible Preferred Stock has a stated value of $100 (the "Stated Value") and accrues dividends daily at an initial rate of 8.0% per annum. The Stated Value, as adjusted to give effect to such dividends, is referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock is convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of the Issuer's Common Stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock is not convertible to the extent that such conversion would result in the holder of such Redeemable Convertible Preferred Stock, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F4: Mr. Meister is a director of the issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 31,822 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 402,326 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F3: Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Ginkgo Bioworks Holdings, Inc.
Report date June 12, 2024 · Filed June 14, 2024
Section 16 reporting ended · disclosed 2024-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 386,480 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 386,480 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Novalis LifeSciences Investments I, L.P. | 5,515,364 |
Reported balance
Holding disclosure · report date 2024-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,515,364 F2: Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00. F3: The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
F3: The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
F4: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 5, 2021 18:08 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000112 · primarydocument.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,080 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2021 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:52 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 27,619 | $32.49 | $897,341.31 |
DisclosureSEC source: 0001562180-20-005393 · primarydocument.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Novalis LifeSciences Investments I, L.P. Disclosed balance after: 0 F1 · shares: Reflects the portion of 117,378 shares of the Issuer's common stock held by Novalis LifeSciences Investments I, L.P. (the "Fund") in which the Reporting Person had a pecuniary interest. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.3489 to $32.5662. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: The Reporting Person had sole voting and investment control over all of the shares owned by the Fund and had a pecuniary interest in 27,619 of the shares. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:04 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $23.12 | $0.00 |
DisclosureSEC source: 0001562180-20-000206 · primarydocument.xml · derivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2030-01-02 F5 · shares: Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:04 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000206 · primarydocument.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,810 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2020 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 16:01 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 30,588 | $15.00 | $458,820.00 |
DisclosureSEC source: 0001104659-19-046955 · a4.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,540 F1 · kind: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer. F1 · price: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 16:01 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 59,171 | $12.92 | $764,489.32 |
DisclosureSEC source: 0001104659-19-046955 · a4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,128 F1 · kind: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer. F1 · price: On August 20, 2019, the Reporting Person transferred an aggregate of 117,378 shares of common stock of Quanterix Corporation (the "Issuer") to Novalis LifeSciences Investments I, L.P (the "Fund"). As the sole member of Novalis LifeSciences Investments I GP, LLC, the general partner of the Fund, the Reporting Person continues to have sole voting and investment control over all of the shares transferred to the Fund. Of the 117,378 shares transferred to the Fund, the Reporting Person's pecuniary interest with respect to 27,619 of the shares did not change. This Form 4 is filed to report the transfer of 89,759 of the shares to the Fund over which the Reporting Person continues to have voting and investment control, but not a pecuniary interest. The shares were transferred to the Fund based on the prices at which the Reporting Person originally purchased the shares from the Issuer. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:01 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $18.24 | $0.00 |
DisclosureSEC source: 0001562180-19-000186 · primarydocument.xml · derivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2029-01-02 F3 · derivative.underlying_shares: Represents non-qualified stock options to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:01 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000186 · primarydocument.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,918 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2019 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:12 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $14.80 | $0.00 |
DisclosureSEC source: 0001104659-18-051028 · a4.xml · derivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2028-08-07 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:12 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-051028 · a4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,648 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2018. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Represents 117,378 shares of common stock and 2,270 restricted stock units. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 20:15 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 5,512 | $14.06 | $77,498.72 |
DisclosureSEC source: 0001231205-18-000052 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,242 Underlying: Common Stock · 5,512 shares Expires not disclosed F1 · security: Acquired at a price of $14.06 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 13:12 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 4,393 | $17.64 | $77,492.52 |
DisclosureSEC source: 0001231205-18-000027 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,418 Underlying: Common Stock · 4,393 shares Expires not disclosed F1 · security: Acquired at a price of $17.64 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:23 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries D-1 Preferred Stock · Derivative | 248,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073152 · a4.xml · derivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:23 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 77,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073152 · a4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. Read SEC document |
| December 11, 2017 Filed Jul 13, 2018 16:06 UTC Amendment | Quanterix Corp QTRX · Entity 6649 | ConversionSeries D-1 Preferred Stock · Derivative | 248,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-045047 · a4a.xml · derivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F3 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| December 11, 2017 Filed Jul 13, 2018 16:06 UTC Amendment | Quanterix Corp QTRX · Entity 6649 | PurchaseCommon Stock | 40,000 | $15.00 | $600,000.00 |
DisclosureSEC source: 0001104659-18-045047 · a4a.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,378 F2 · shares: Reflects shares of common stock purchased in the Issuer's initial public offering. This amendment is being filed solely to report this purchase of shares of common stock, which was inadvertently omitted from the Form 4 filed on December 11, 2017. Read SEC document |
| December 11, 2017 Filed Jul 13, 2018 16:06 UTC Amendment | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 77,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-045047 · a4a.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 20:10 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 3,176 | $24.40 | $77,494.40 |
DisclosureSEC source: 0001231205-17-000121 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 3,176 shares Expires not disclosed F1 · security: Acquired at a price of $24.40 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 20:15 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 2,773 | $27.95 | $77,505.35 |
DisclosureSEC source: 0001231205-17-000063 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,087 Underlying: Common Stock · 2,773 shares Expires not disclosed F1 · security: Acquired at a price of $27.95 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 20:00 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | PurchaseCommon Stock | 20,000 | $29.90 | $598,000.00 |
DisclosureSEC source: 0001231205-17-000045 · edgar.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Irrevocable Trust Disclosed balance after: 40,000 F1 · security: All tansactions reported on this Form 4 were conducted through a internal systemizer. Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 20:08 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 2,606 | $29.74 | $77,502.44 |
DisclosureSEC source: 0001231205-17-000032 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,050 Underlying: Common Stock · 2,606 shares Expires not disclosed F1 · security: Acquired at a price of $29.74 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:28 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 2,446 | $31.68 | $77,489.28 |
DisclosureSEC source: 0001231205-17-000014 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,209 Underlying: Common Stock · 2,446 shares Expires not disclosed F1 · security: Acquired at a price of $31.68 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:13 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 2,577 | $30.07 | $77,490.39 |
DisclosureSEC source: 0001231205-16-000187 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,546 Underlying: Common Stock · 2,577 shares Expires not disclosed F1 · security: Acquired at a price of $30.07 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F4 · security: All transactions reported on this Form 4 were conducted outside a trading venue. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| July 01, 2016 Filed Jul 5, 2016 20:07 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,357 | $30.39 | $41,239.23 |
DisclosureSEC source: 0001231205-16-000144 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,784 Underlying: Common Stock · 1,357 shares Expires not disclosed F1 · security: Acquired at a price of $30.39 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 15:24 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,342 | $30.74 | $41,253.08 |
DisclosureSEC source: 0001231205-16-000132 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,247 Underlying: Common Stock · 1,342 shares Expires not disclosed F1 · security: Acquired at a price of $30.74 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| January 04, 2016 Filed Jan 4, 2016 22:45 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,348 | $30.60 | $41,248.80 |
DisclosureSEC source: 0001231205-16-000094 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,722 Underlying: Common Stock · 1,348 shares Expires not disclosed F1 · security: Acquired at a price of $30.60 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| October 01, 2015 Filed Oct 2, 2015 18:37 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,658 | $24.88 | $41,251.04 |
DisclosureSEC source: 0001231205-15-000066 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,214 Underlying: Common Stock · 1,658 shares Expires not disclosed F1 · security: Acquired at a price of $24.88 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| July 01, 2015 Filed Jul 1, 2015 20:31 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,514 | $27.25 | $41,256.50 |
DisclosureSEC source: 0001231205-15-000037 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,388 Underlying: Common Stock · 1,514 shares Expires not disclosed F1 · security: Acquired at a price of $27.25 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| April 22, 2015 Filed Apr 23, 2015 17:53 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | PurchaseCommon Stock | 20,000 | $26.93 | $538,600.00 |
DisclosureSEC source: 0001231205-15-000030 · edgar.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,000 Read SEC document |
| April 01, 2015 Filed Apr 4, 2015 01:20 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,635 | $25.24 | $41,267.40 |
DisclosureSEC source: 0001206774-15-001165 · dekkers.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,728 Underlying: Common Stock · 1,635 shares Expires not disclosed F1 · security: Acquired at a price of $25.24 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| January 02, 2015 Filed Jan 5, 2015 22:05 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,619 | $25.48 | $41,252.12 |
DisclosureSEC source: 0001231205-15-000005 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 Underlying: Common Stock · 1,619 shares Expires not disclosed F1 · security: Acquired at a price of $25.48 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| October 01, 2014 Filed Oct 1, 2014 20:00 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,590 | $25.95 | $41,260.50 |
DisclosureSEC source: 0001231205-14-000085 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,214 Underlying: Common Stock · 1,590 shares Expires not disclosed F1 · security: Acquired at a price of $25.95 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 19:03 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,538 | $26.82 | $41,249.16 |
DisclosureSEC source: 0001231205-14-000057 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,522 Underlying: Common Stock · 1,538 shares Expires not disclosed F1 · security: Acquired at a price of $26.82 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| April 01, 2014 Filed Apr 3, 2014 20:58 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,607 | $25.67 | $41,251.69 |
DisclosureSEC source: 0001231205-14-000034 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,899 Underlying: Common Stock · 1,607 shares Expires not disclosed F1 · security: Acquired at a price of $25.67 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| December 31, 2013 Filed Jan 3, 2014 20:40 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,518 | $27.18 | $41,259.24 |
DisclosureSEC source: 0001231205-14-000004 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,216 Underlying: Common Stock · 1,518 shares Expires not disclosed F1 · security: Acquired at a price of $27.18 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| October 01, 2013 Filed Oct 3, 2013 19:46 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,724 | $23.92 | $41,238.08 |
DisclosureSEC source: 0001231205-13-000110 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,647 Underlying: Common Stock · 1,724 shares Expires not disclosed F1 · security: Acquired at a price of $23.92 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 22:27 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,594 | $23.52 | $37,490.88 |
DisclosureSEC source: 0001231205-13-000062 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,724 Underlying: Common Stock · 1,594 shares Expires not disclosed F1 · security: Acquired at a price of $23.52 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| April 02, 2013 Filed Apr 3, 2013 18:39 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,602 | $23.40 | $37,486.80 |
DisclosureSEC source: 0001231205-13-000028 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,099 Underlying: Common Stock · 1,602 shares Expires not disclosed F1 · security: Acquired at a price of $23.40 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| January 02, 2013 Filed Jan 4, 2013 21:57 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,769 | $21.20 | $37,502.80 |
DisclosureSEC source: 0001231205-13-000004 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,482 Underlying: Common Stock · 1,769 shares Expires not disclosed F1 · security: Acquired at a price of $21.20 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| December 27, 2012 Filed Dec 19, 2013 19:44 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | PurchaseCommon Stock | 1,000 | $20.58 | $20,580.00 |
DisclosureSEC source: 0001231205-13-000130 · edgar.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · date: Transaction information inadvertently filed late due to an administrative error Read SEC document |
| October 01, 2012 Filed Oct 1, 2012 21:31 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantDeferred Fee Phantom Stock Units · Derivative | 1,713 | $21.89 | $37,497.57 |
DisclosureSEC source: 0001231205-12-000113 · edgar.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,713 Underlying: Common Stock · 1,713 shares Expires not disclosed F1 · security: Acquired at a price of $21.89 per unit pursuant to the terms of the 2003 Non-Employee Director Compensation Plan. Payable beginning one year after termination of service as a director. F2 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F3 · derivative.exercise_date: Payable beginning one year after termination of service as a director. F3 · derivative.expiration_date: Payable beginning one year after termination of service as a director. Read SEC document |
| August 17, 2009 Filed Aug 18, 2009 22:08 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 4,927 | $44.76 | $220,532.52 |
DisclosureSEC source: 0001225208-09-017503 · doc4.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,554 Read SEC document |
| August 17, 2009 Filed Aug 18, 2009 22:08 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 23,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-017503 · doc4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,481 F1 · shares: Represents shares awarded as performance restricted stock awards on November 9, 2006, for which the performance criteria have been satisfied. Read SEC document |
| July 08, 2009 Filed Jul 9, 2009 18:15 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantPhantom Stock (Time-Based) · Derivative | 62,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-015516 · doc4.xml · derivative · entry 4 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of TMO common stock. F4 · derivative.exercise_date: This award vests with respect to 30% of the shares subject to the award on December 31, 2014 and with respect to the remaining 70% of such shares on December 31, 2017. F5 · derivative.expiration_date: This award settles on the date of the reporting person's separation from service with the company. Read SEC document |
| July 08, 2009 Filed Jul 9, 2009 18:15 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantPhantom Stock (Performance-Based) · Derivative | 62,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-015516 · doc4.xml · derivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of TMO common stock. F3 · shares: The number of shares subject to this award varies between 0% and 200% of the figure shown based on the company's total shareholder return relative to the performance of the S&P Industrials Composite Index over the period from January 1, 2008 to the earlier of the reporting person's separation from service and December 31, 2017. F4 · derivative.exercise_date: This award vests with respect to 30% of the shares subject to the award on December 31, 2014 and with respect to the remaining 70% of such shares on December 31, 2017. F5 · derivative.expiration_date: This award settles on the date of the reporting person's separation from service with the company. F3 · balance_after: The number of shares subject to this award varies between 0% and 200% of the figure shown based on the company's total shareholder return relative to the performance of the S&P Industrials Composite Index over the period from January 1, 2008 to the earlier of the reporting person's separation from service and December 31, 2017. Read SEC document |
| January 07, 2009 Filed Jan 9, 2009 20:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 1,168 | $34.92 | $40,786.56 |
DisclosureSEC source: 0001225208-09-001216 · doc4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,141 Read SEC document |
| November 09, 2008 Filed Nov 10, 2008 23:42 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 6,569 | $37.73 | $247,848.37 |
DisclosureSEC source: 0001225208-08-017691 · doc4.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,309 Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 22:09 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 146,000 | $0.00 Strike: $27.40 | $0.00 |
DisclosureSEC source: 0001225208-08-013274 · doc4.xml · derivative · entry 4 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,000 shares Expires 2012-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on February 25, 2006. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 22:09 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 146,000 | $59.96 | $8,754,160.00 |
DisclosureSEC source: 0001225208-08-013274 · doc4.xml · nonDerivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,878 F2 · price: The price in Column 4 is a weighted average price. The prices actually received ranged from $59.74 to $60.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 22:09 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 146,000 | $27.40 | $4,000,400.00 |
DisclosureSEC source: 0001225208-08-013274 · doc4.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.